Clinical Trial Update: The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study investigating the safety and feasibility of using 5-aminolevulinic acid (ALA) as an intraoperative tumor …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Tumor

Drugs mentioned

• 5-aminolevulinic acid (5-aminolevulinic acid)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Central Nervous System Tumor, Pediatric | Phase 1, Phase 2 | Status: UNKNOWN